Lev Barats, MD
Internal Medicine · Slingerlands, NYNPI 1760492680
Payments from drug & device makers
Across 201 payments — averaging $15.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$424
- AstraZeneca$326
- Renalytix AI, Inc.$298
- GSK$276
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$198
- Novo Nordisk$198
- plus $1K from 21 others
Across 3 payments — averaging $4740.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Renalytix AI, Inc.$14K
What the payments were for
- Food & beverage$3,114100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 37 | $424 |
| AstraZeneca | 22 | $326 |
| Renalytix AI, Inc. | 21 | $298 |
| GSK | 19 | $276 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $198 |
| Novo Nordisk | 11 | $198 |
| Amgen(2 entities) | 11 | $197 |
| Pfizer | 9 | $165 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $139 |
| Radius Health, Inc. | 9 | $138 |
| Johnson & Johnson | 6 | $114 |
| Boehringer Ingelheim | 4 | $83 |
| Novartis | 3 | $74 |
| Amarin Pharma, Inc. | 4 | $71 |
| Merck | 5 | $63 |
| Endo Pharmaceuticals Inc. | 3 | $58 |
| Teva Pharmaceuticals USA, Inc. | 4 | $47 |
| Astellas Pharma US Inc | 2 | $37 |
| Boston Scientific | 1 | $34 |
| Sanofi Pasteur Inc. | 2 | $30 |
| Idorsia Pharmaceuticals US Inc | 1 | $24 |
| Lilly USA, LLC | 2 | $24 |
| Collegium Pharmaceutical, Inc. | 1 | $22 |
| Dexcom, Inc. | 1 | $21 |
| Lundbeck LLC | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,114 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 138 | $178,691 |
| EliquisApixaban | 166 | $178,157 |
| OzempicSemaglutide | 57 | $96,726 |
| JardianceEmpagliflozin | 68 | $79,640 |
| ProliaDenosumab | 42 | $72,353 |
| FarxigaDapagliflozin Propanediol | 48 | $69,833 |
| Breo ElliptaFluticasone/Vilanterol | 81 | $56,268 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $49,646 |
| TradjentaLinagliptin | 29 | $41,709 |
| MyrbetriqMirabegron | 33 | $40,583 |
| TrulicityDulaglutide | 28 | $39,892 |
| JanumetSitagliptin Phos/Metformin Hcl | 25 | $36,987 |
| EntrestoSacubitril/Valsartan | 21 | $22,158 |
| MounjaroTirzepatide | 18 | $20,733 |
| OxycontinOxycodone Hcl | 25 | $19,164 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet, Janumet Xr | $63 | $223,045175 claims |
| PfizerEliquis, Effexor Xr | $165 | $185,470179 claims |
| Boehringer IngelheimJardiance, Tradjenta | $83 | $121,34997 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta | $276 | $116,391138 claims |
| Novo NordiskOzempic | $198 | $96,72657 claims |
| AstraZenecaFarxiga, Nexium, Symbicort | $326 | $95,71379 claims |
| AmgenProlia | $197 | $72,35342 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $24 | $60,62546 claims |
| Astellas Pharma US IncMyrbetriq | $37 | $40,58333 claims |
| AbbVieLinzess, Synthroid | $424 | $23,040112 claims |
| NovartisEntresto | $74 | $22,15821 claims |
| Johnson & JohnsonXarelto | $114 | $15,05612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Slingerlands
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.